Ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: Nadroparin reduces the incidence of thromboembolic events


Clinical trials are needed to assess the clinical benefit of antithrombotic prophylaxis in patients with cancer who are receiving chemotherapy, since these patients are at an increased risk of developing a thromboembolism.

PROTECHT Investigators did a trial to assess the clinical benefit of the low molecular weight Heparin ( LMWH ) Nadroparin ( Seleparina ) for the prophylaxis of thromboembolic events in ambulatory patients receiving chemotherapy for metastatic or locally advanced solid cancer.

During the period 2003-2007, ambulatory patients with lung, gastrointestinal, pancreatic, breast, ovarian, or head and neck cancer were randomly assigned in a double-blind manner to receive subcutaneous injections of Nadroparin ( 3800 IU anti-Xa once a day, n=779 ) or placebo ( n=387 ), in a 2:1 ratio.
Study treatment was given for the duration of chemotherapy up to a maximum of 4 months.

The primary study outcome was the composite of symptomatic venous or arterial thromboembolic events, as assessed by an independent adjudication Committee.

All randomised patients who received at least one dose of study treatment were included in the efficacy and safety analyses ( modified intention-to-treat population ).

1150 patients were included in the primary efficacy and safety analyses: 769 patients in the Nadroparin group and 381 patients in the placebo group.

15 ( 2.0% ) of 769 patients treated with Nadroparin and 15 ( 3.9% ) of 381 patients treated with placebo had a thromboembolic event ( single-sided p=0.02 ).

Five ( 0.7% ) of 769 patients in the Nadroparin group and no patients in the placebo group had a major bleeding event ( two-sided p=0.18 ).
The incidences of minor bleeding were 7.4% ( 57 of 769 ) with Nadroparin and 7.9% ( 30 of 381 ) with placebo.

There were 121 ( 15.7% ) serious adverse events in the Nadroparin group and 67 ( 17.6% ) serious adverse events in the placebo group.

In conclusion, Nadroparin reduces the incidence of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer who are receiving chemotherapy.
Future studies should focus on patients who are at a high risk for thromboembolic events. ( Xagena )

Agnelli G et al, Lancet Oncol 2009;10:943-949

XagenaMedicine_2009



Indietro

Altri articoli

Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device...


Controversy persists over statins and risk of intracerebral hemorrhage. Researchers have determined associations of premorbid lipid-lowering therapy and outcomes among...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk...


Even a single additional stroke risk factor in patients with atrial fibrillation may confer a risk of stroke. However, there...


ESC Guidelines recommended for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention ( PCI...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively....


Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients...


Women suffer more disabling strokes than men and need to become better aware of their unique risk factors, according to...


For patients with atrial fibrillation or atrial flutter of 48-hour duration or longer, or when the duration of atrial fibrillation...